177 related articles for article (PubMed ID: 24325203)
1. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.
Weiduschat N; Mao X; Beal MF; Nirenberg MJ; Shungu DC; Henchcliffe C
J Neuroimaging; 2015; 25(1):105-10. PubMed ID: 24325203
[TBL] [Abstract][Full Text] [Related]
2. Detection and application of neurochemical profile by multiple regional
Guan J; Rong Y; Wen Y; Wu H; Qin H; Zhang Q; Chen W
Brain Behav; 2017 Sep; 7(9):e00792. PubMed ID: 28948086
[TBL] [Abstract][Full Text] [Related]
3. Whole-brain proton MR spectroscopic imaging in Parkinson's disease.
Levin BE; Katzen HL; Maudsley A; Post J; Myerson C; Govind V; Nahab F; Scanlon B; Mittel A
J Neuroimaging; 2014; 24(1):39-44. PubMed ID: 23228009
[TBL] [Abstract][Full Text] [Related]
4. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
5. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
[TBL] [Abstract][Full Text] [Related]
6. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
Seraji-Bozorgzad N; Bao F; George E; Krstevska S; Gorden V; Chorostecki J; Santiago C; Zak I; Caon C; Khan O
Mov Disord; 2015 Sep; 30(10):1400-4. PubMed ID: 26228901
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
Ciurleo R; Di Lorenzo G; Bramanti P; Marino S
Biomed Res Int; 2014; 2014():519816. PubMed ID: 25302300
[TBL] [Abstract][Full Text] [Related]
9. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Lucetti C; Del Dotto P; Gambaccini G; Bernardini S; Bianchi MC; Tosetti M; Bonuccelli U
Neurol Sci; 2001 Feb; 22(1):69-70. PubMed ID: 11487206
[TBL] [Abstract][Full Text] [Related]
10. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease.
Hattingen E; Magerkurth J; Pilatus U; Mozer A; Seifried C; Steinmetz H; Zanella F; Hilker R
Brain; 2009 Dec; 132(Pt 12):3285-97. PubMed ID: 19952056
[TBL] [Abstract][Full Text] [Related]
11. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
[TBL] [Abstract][Full Text] [Related]
12. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
Brockmann K; Hilker R; Pilatus U; Baudrexel S; Srulijes K; Magerkurth J; Hauser AK; Schulte C; Csoti I; Merten CD; Gasser T; Berg D; Hattingen E
Neurology; 2012 Jul; 79(3):213-20. PubMed ID: 22722629
[TBL] [Abstract][Full Text] [Related]
13. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Clarke CE; Lowry M; Horsman A
Mov Disord; 1997 May; 12(3):297-301. PubMed ID: 9159722
[TBL] [Abstract][Full Text] [Related]
14. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Aotsuka A; Shinotoh H; Hattori T
Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459
[TBL] [Abstract][Full Text] [Related]
15. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
[TBL] [Abstract][Full Text] [Related]
16. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease.
Henchcliffe C; Shungu DC; Mao X; Huang C; Nirenberg MJ; Jenkins BG; Beal MF
Ann N Y Acad Sci; 2008 Dec; 1147():206-20. PubMed ID: 19076443
[TBL] [Abstract][Full Text] [Related]
17. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
18. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Meyerhoff DJ; MacKay S; Constans JM; Norman D; Van Dyke C; Fein G; Weiner MW
Ann Neurol; 1994 Jul; 36(1):40-7. PubMed ID: 8024260
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Braak staging of brain pathology with
Cao H; Shi J; Cao B; Kang B; Zhang M; Qu Q
Neurosci Lett; 2017 Nov; 660():57-62. PubMed ID: 28844732
[TBL] [Abstract][Full Text] [Related]
20. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Zhou B; Yuan F; He Z; Tan C
Brain Imaging Behav; 2014 Mar; 8(1):97-101. PubMed ID: 23955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
